In the 20 17 ranking of the world's top 500 companies, Gilead Scientific Company ranked 92nd. On May 3, 2020 18, Gilead Science ranked in the 2020 Forbes Global Top 2000 list 186.
Enterprise introduction
Founded on June 22nd, 1987, Gilead Technology is a research-oriented biopharmaceutical company, which researches, develops and produces drugs in areas where medical needs are not met.
The company's product portfolio and research drug pipeline include the treatment of human immunodeficiency virus acquired immunodeficiency syndrome (HIV/AIDS), liver disease, cancer, inflammatory and respiratory diseases and cardiovascular diseases.
Its products include AmBisome, Atripla, Cayston, Complera/Eviplera, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera and Letairis.
The company's key research areas include HIV, liver diseases such as hepatitis C virus (HCV) infection and hepatitis B virus (HBV) infection; Blood/tumor; Cardiovascular diseases and inflammatory/respiratory diseases.
By the end of 20 16 12 3 1, the company has started business in more than 30 countries. The company is engaged in the development of cancer immunotherapy through its subsidiary Kite Pharma, Inc.(Kite). Kite Company focuses on engineering cell therapy of chimeric antigen receptor (CAR) and T cell receptor (TCR), aiming at enhancing the immune system's ability to recognize and kill tumors.